Dyslipidemia – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of dyslipidemia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dyslipidemia for each country, as well as annualized case counts projected to the national population.

Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan, and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s dyslipidemia forecast will answer the following questions:

• Of all people with dyslipidemia, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?
• Of all people diagnosed with dyslipidemia, how many in each country across the major mature pharmaceutical markets are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of dyslipidemia over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, for the major mature pharmaceutical markets, we provide graphs depicting the patient flow between or within different disease states. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

In total, Clarivate Epidemiology forecasts 26 dyslipidemia patient populations, as follows:

• High LDL only secondary prevention.
• Diagnosed secondary prevention prevalent cases.
• Mixed dyslipidemia prevalent cases.
• Low HDL only primary prevention.
• Diagnosed drug-treated primary prevention prevalent cases.
• High LDL only primary prevention.
• Undiagnosed secondary prevention prevalent cases.
• Diagnosed primary prevention prevalent cases.
• Diagnosed drug-treated secondary prevention prevalent cases.
• Total prevalent cases.
• … and many more (details available on request).

Note: Coverage may vary by country.